258 related articles for article (PubMed ID: 21940710)
21. Cheminformatics approaches to analyze diversity in compound screening libraries.
Akella LB; DeCaprio D
Curr Opin Chem Biol; 2010 Jun; 14(3):325-30. PubMed ID: 20457001
[TBL] [Abstract][Full Text] [Related]
22. The Interweaving of Cheminformatics and HTS.
Kümmel A; Parker CN
Methods Mol Biol; 2011; 672():435-57. PubMed ID: 20838979
[TBL] [Abstract][Full Text] [Related]
23. Fluorescence labels in kinases: a high-throughput kinase binding assay for the identification of DFG-out binding ligands.
Simard JR; Rauh D
Methods Mol Biol; 2012; 800():95-117. PubMed ID: 21964785
[TBL] [Abstract][Full Text] [Related]
24. The holistic integration of virtual screening in drug discovery.
Tanrikulu Y; Krüger B; Proschak E
Drug Discov Today; 2013 Apr; 18(7-8):358-64. PubMed ID: 23340112
[TBL] [Abstract][Full Text] [Related]
25. Use of high-throughput mass spectrometry to reduce false positives in protease uHTS screens.
Adam GC; Meng J; Rizzo JM; Amoss A; Lusen JW; Patel A; Riley D; Hunt R; Zuck P; Johnson EN; Uebele VN; Hermes JD
J Biomol Screen; 2015 Feb; 20(2):212-22. PubMed ID: 25336354
[TBL] [Abstract][Full Text] [Related]
26. Enhancements of screening collections to address areas of unmet medical need: an industry perspective.
Drewry DH; Macarron R
Curr Opin Chem Biol; 2010 Jun; 14(3):289-98. PubMed ID: 20413343
[TBL] [Abstract][Full Text] [Related]
27. Development of a high-throughput screening assay for stearoyl-CoA desaturase using rat liver microsomes, deuterium labeled stearoyl-CoA and mass spectrometry.
Soulard P; McLaughlin M; Stevens J; Connolly B; Coli R; Wang L; Moore J; Kuo MS; LaMarr WA; Ozbal CC; Bhat BG
Anal Chim Acta; 2008 Oct; 627(1):105-11. PubMed ID: 18790133
[TBL] [Abstract][Full Text] [Related]
28. An improved zinc cocktail-mediated fluorescence polarization-based kinase assay for high-throughput screening of kinase inhibitors.
Chopra P; Nanda K; Chatterjee M; Bajpai M; Dastidar SG; Ray A
Anal Biochem; 2008 Sep; 380(1):143-5. PubMed ID: 18570885
[TBL] [Abstract][Full Text] [Related]
29. Recent progress in fragment-based lead discovery.
Schulz MN; Hubbard RE
Curr Opin Pharmacol; 2009 Oct; 9(5):615-21. PubMed ID: 19477685
[TBL] [Abstract][Full Text] [Related]
30. Biomarkers for simplifying HTS 3D cell culture platforms for drug discovery: the case for cytokines.
Lai Y; Asthana A; Kisaalita WS
Drug Discov Today; 2011 Apr; 16(7-8):293-7. PubMed ID: 21277382
[TBL] [Abstract][Full Text] [Related]
31. The zebrafish: a powerful platform for in vivo, HTS drug discovery.
Delvecchio C; Tiefenbach J; Krause HM
Assay Drug Dev Technol; 2011 Aug; 9(4):354-61. PubMed ID: 21309713
[TBL] [Abstract][Full Text] [Related]
32. Discovery of antagonists for human scavenger receptor CD36 via an ELISA-like high-throughput screening assay.
Wang L; Bao Y; Yang Y; Wu Y; Chen X; Si S; Hong B
J Biomol Screen; 2010 Mar; 15(3):239-50. PubMed ID: 20150587
[TBL] [Abstract][Full Text] [Related]
33. A dual-readout F2 assay that combines fluorescence resonance energy transfer and fluorescence polarization for monitoring bimolecular interactions.
Du Y; Nikolovska-Coleska Z; Qui M; Li L; Lewis I; Dingledine R; Stuckey JA; Krajewski K; Roller PP; Wang S; Fu H
Assay Drug Dev Technol; 2011 Aug; 9(4):382-93. PubMed ID: 21395401
[TBL] [Abstract][Full Text] [Related]
34. Non-stoichiometric inhibition in integrated lead finding - a literature review.
Klumpp M
Expert Opin Drug Discov; 2016; 11(2):149-62. PubMed ID: 26653534
[TBL] [Abstract][Full Text] [Related]
35. Experimental design and statistical methods for improved hit detection in high-throughput screening.
Malo N; Hanley JA; Carlile G; Liu J; Pelletier J; Thomas D; Nadon R
J Biomol Screen; 2010 Sep; 15(8):990-1000. PubMed ID: 20817887
[TBL] [Abstract][Full Text] [Related]
36. Big pharma screening collections: more of the same or unique libraries? The AstraZeneca-Bayer Pharma AG case.
Kogej T; Blomberg N; Greasley PJ; Mundt S; Vainio MJ; Schamberger J; Schmidt G; Hüser J
Drug Discov Today; 2013 Oct; 18(19-20):1014-24. PubMed ID: 23127858
[TBL] [Abstract][Full Text] [Related]
37. Optimal HTS Fingerprint Definitions by Using a Desirability Function and a Genetic Algorithm.
Cortes Cabrera A; Petrone PM
J Chem Inf Model; 2018 Mar; 58(3):641-646. PubMed ID: 29425455
[TBL] [Abstract][Full Text] [Related]
38. Applications of Biophysics in High-Throughput Screening Hit Validation.
Genick CC; Barlier D; Monna D; Brunner R; Bé C; Scheufler C; Ottl J
J Biomol Screen; 2014 Jun; 19(5):707-14. PubMed ID: 24695619
[TBL] [Abstract][Full Text] [Related]
39. Improving lead generation success through integrated methods: transcending 'drug discovery by numbers'.
Campbell JB
IDrugs; 2010 Dec; 13(12):874-9. PubMed ID: 21154146
[TBL] [Abstract][Full Text] [Related]
40. Recent trends and observations in the design of high-quality screening collections.
Renner S; Popov M; Schuffenhauer A; Roth HJ; Breitenstein W; Marzinzik A; Lewis I; Krastel P; Nigsch F; Jenkins J; Jacoby E
Future Med Chem; 2011 Apr; 3(6):751-66. PubMed ID: 21554080
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
